Digital Aria Co Ltd - Asset Resilience Ratio
Digital Aria Co Ltd (115450) has an Asset Resilience Ratio of 0.96% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Digital Aria Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Digital Aria Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 115450 asset base.
Liquid Assets Composition Over Time
This chart breaks down Digital Aria Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Digital Aria Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩2.20 Billion | 0.96% |
| Total Liquid Assets | ₩2.20 Billion | 0.96% |
Asset Resilience Insights
- Limited Liquidity: Digital Aria Co Ltd maintains only 0.96% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Digital Aria Co Ltd Industry Peers by Asset Resilience Ratio
Compare Digital Aria Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Digital Aria Co Ltd (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Digital Aria Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.23% | ₩25.69 Billion ≈ $17.41 Million |
₩228.66 Billion ≈ $154.96 Million |
-5.95pp |
| 2024-12-31 | 17.19% | ₩37.77 Billion ≈ $25.60 Million |
₩219.79 Billion ≈ $148.95 Million |
+1.07pp |
| 2023-12-31 | 16.11% | ₩32.35 Billion ≈ $21.92 Million |
₩200.79 Billion ≈ $136.08 Million |
-17.97pp |
| 2022-12-31 | 34.08% | ₩63.95 Billion ≈ $43.34 Million |
₩187.64 Billion ≈ $127.16 Million |
-18.90pp |
| 2021-12-31 | 52.98% | ₩100.51 Billion ≈ $68.11 Million |
₩189.71 Billion ≈ $128.56 Million |
+29.37pp |
| 2020-12-31 | 23.61% | ₩28.79 Billion ≈ $19.51 Million |
₩121.94 Billion ≈ $82.64 Million |
-10.90pp |
| 2019-12-31 | 34.51% | ₩48.15 Billion ≈ $32.63 Million |
₩139.52 Billion ≈ $94.55 Million |
+18.85pp |
| 2018-12-31 | 15.66% | ₩16.85 Billion ≈ $11.42 Million |
₩107.66 Billion ≈ $72.96 Million |
+6.24pp |
| 2017-12-31 | 9.42% | ₩5.91 Billion ≈ $4.00 Million |
₩62.71 Billion ≈ $42.50 Million |
+0.55pp |
| 2016-12-31 | 8.87% | ₩4.58 Billion ≈ $3.11 Million |
₩51.65 Billion ≈ $35.00 Million |
+0.93pp |
| 2015-12-31 | 7.94% | ₩4.00 Billion ≈ $2.71 Million |
₩50.35 Billion ≈ $34.12 Million |
-4.02pp |
| 2014-12-31 | 11.96% | ₩7.00 Billion ≈ $4.74 Million |
₩58.52 Billion ≈ $39.66 Million |
+11.37pp |
| 2013-12-31 | 0.59% | ₩216.00 Million ≈ $146.38K |
₩36.69 Billion ≈ $24.86 Million |
+0.01pp |
| 2012-12-31 | 0.58% | ₩313.70 Million ≈ $212.59K |
₩54.32 Billion ≈ $36.81 Million |
-6.93pp |
| 2011-12-31 | 7.51% | ₩4.67 Billion ≈ $3.17 Million |
₩62.23 Billion ≈ $42.17 Million |
-- |
About Digital Aria Co Ltd
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrica… Read more